GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Asset Turnover

INBX (Inhibrx Biosciences) Asset Turnover : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Inhibrx Biosciences's Revenue for the three months ended in Dec. 2024 was $0.10 Mil. Inhibrx Biosciences's Total Assets for the quarter that ended in Dec. 2024 was $201.66 Mil. Therefore, Inhibrx Biosciences's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Inhibrx Biosciences's annualized ROE % for the quarter that ended in Dec. 2024 was -122.71%. It is also linked to ROA % through Du Pont Formula. Inhibrx Biosciences's annualized ROA % for the quarter that ended in Dec. 2024 was -94.94%.


Inhibrx Biosciences Asset Turnover Historical Data

The historical data trend for Inhibrx Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Asset Turnover Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Asset Turnover
0.08 0.01 -

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only 0.01 - - - -

Competitive Comparison of Inhibrx Biosciences's Asset Turnover

For the Biotechnology subindustry, Inhibrx Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx Biosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Asset Turnover falls into.


;
;

Inhibrx Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Inhibrx Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.2/( (307.893+180.767)/ 2 )
=0.2/244.33
=0.00

Inhibrx Biosciences's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.1/( (222.562+180.767)/ 2 )
=0.1/201.6645
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Inhibrx Biosciences  (NAS:INBX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Inhibrx Biosciences's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-191.46/156.0255
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-191.46 / 0.4)*(0.4 / 201.6645)*(201.6645/ 156.0255)
=Net Margin %*Asset Turnover*Equity Multiplier
=-47865 %*0.002*1.2925
=ROA %*Equity Multiplier
=-94.94 %*1.2925
=-122.71 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Inhibrx Biosciences's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-191.46/201.6645
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-191.46 / 0.4)*(0.4 / 201.6645)
=Net Margin %*Asset Turnover
=-47865 %*0.002
=-94.94 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Inhibrx Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.